Finally, we assessed the therapeutic potential of targeting eIFs by performing siRNA knockdown experiments for eIF1, eIF5 and eIF6 in two CRC cell lines (HCT116, HT29). This evidence concerns the gene EIF5 and colorectal carcinoma.